Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 20/20 | 0.51 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293034 | 1.00 | MALT1 (0.51) | MALT1BIRC3HTR7TMEM97SIGMAR1 | |
| SCHEMBL17293107 | 0.89 | MALT1 (0.50) | MALT1BIRC3 | |
| SCHEMBL17293109 | 0.89 | MALT1 (0.50) | MALT1BIRC3 | |
| SCHEMBL25869771 | 0.88 | MALT1 (0.57) | MALT1BIRC3HTR7TMEM97SIGMAR1 | |
| SCHEMBL18862728 | 0.87 | MALT1 (0.46) | MALT1BIRC3HTR7TMEM97SIGMAR1 | |
| SCHEMBL17293077 | 0.87 | MALT1 (0.49) | MALT1BIRC3 | |
| SCHEMBL17293075 | 0.87 | MALT1 (0.49) | MALT1BIRC3 | |
| SCHEMBL17292964 | 0.86 | MALT1 (0.40) | MALT1BIRC3HTR7TMEM97SIGMAR1 | |
| SCHEMBL17292962 | 0.86 | MALT1 (0.40) | MALT1BIRC3HTR7TMEM97SIGMAR1 | |
| SCHEMBL20913178 | 0.85 | MALT1 (0.41) | MALT1BIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092066-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-03-20 | — | — | US | disclosed |
| EP-4466268-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | Aurigene Oncology Limited (IN) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023139479-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-07-27 | — | — | WO | disclosed |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | NOVARTIS PHARMA AG (CH) | 2020-09-17 | — | — | US | disclosed |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | NOVARTIS AG (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3149001-B1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| EP-3374361-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9815842-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| WO-2017081641-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017081641-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| EP-3149001-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | Novartis AG (CH) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181747-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | NOVARTIS AG (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | MALT1 2/4885BIRC3 13/4885HTR7 4728/4885 |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | MMEL1, PPME1, CTSC | MALT1 4/4885BIRC3 49/4885HTR7 4520/4885 |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | MALT1 2/4885BIRC3 13/4885HTR7 4728/4885 |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | FBP1, MMEL1, MALT1 | MALT1 3/4885BIRC3 40/4885HTR7 4706/4885 |
| US-20250092066-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | MALT1, FKBP1B, FKBP1A | MALT1 1/4885BIRC3 99/4885HTR7 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.